Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 3/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.32 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.30 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651198 | 0.82 | KMT2A (0.38) | CYP2A6PIP4K2APIP4K2CSCN9AOXTR | |
| Fumaric Acid SCHEMBL4119118 | 0.78 | NFE2L2 (0.35) | NFE2L2CYP2A6 | |
| Fumaric Acid SCHEMBL4119125 | 0.78 | NFE2L2 (0.35) | NFE2L2CYP2A6 | |
| SCHEMBL3655764 | 0.77 | CYP2A6 (0.39) | CYP2A6PIP4K2APIP4K2C | |
| SCHEMBL3654418 | 0.77 | PIP4K2A (0.39) | NFE2L2CYP2A6PIP4K2APIP4K2C | |
| SCHEMBL4119121 | 0.75 | NFE2L2 (0.33) | NFE2L2 | |
| SCHEMBL3646540 | 0.75 | PTGS2 (0.36) | CYP2A6PIP4K2APIP4K2C | |
| SCHEMBL3649066 | 0.75 | FEN1 (0.39) | NFE2L2CYP2A6 | |
| SCHEMBL3691530 | 0.73 | NAMPT (0.35) | CYP2A6PIP4K2APIP4K2CCTSDBACE1 | |
| SCHEMBL3700772 | 0.73 | CYP2A6 (0.39) | CYP2A6PIP4K2APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NFE2L2 2670/4885CYP2A6 443/4885PDE2A 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.